| 08:30 | P1898 | Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries | Giulia MONTRASIO (Zurich, Switzerland) |
|
| 08:30 | P1899 | Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study | Walid AMARA (Le Raincy-Montfermeil, France) |
|
| 08:30 | P1900 | Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation | Miroslav MIHAJLOVIC (Belgrade, Serbia) |
|
| 08:30 | P1901 | Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging | Masahide HARADA (Toyoake, Japan) |
|
| 08:30 | P1902 | Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples | Orsolya HAJAS (Debrecen, Hungary) |
|
| 08:30 | P1903 | Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials | Harry CRIJNS (Maastricht, Netherlands (The)) |
|
| 08:30 | P1904 | Oral anticoagulation in patients undergoing elective cardioversion of atrial fibrillation. Real-life experience from Finland | Saga ITAINEN-STROMBERG (Helsinki, Finland) |
|
| 08:30 | P1905 | Propofol suppresses atrial fibrillation in an experimental whole-heart model | Julian WOLFES (Munster, Germany) |
|
| 08:30 | P1906 | Modified frailty as a novel factor to predict the effectiveness of electrical cardioversion of atrial fibrillation in the elderly population | Agnieszka MLYNARSKA (Myslowice, Poland) |
|
| 08:30 | P1907 | Propensity score matched analysis of antazoline mesylate vs. amiodarone or propafenone for pharmacological cardioversion of short-duration atrial fibrillation | Maciej WYBRANIEC (Katowice, Poland) |
|